It belongs to a class of agents known as multi-incretin receptor agonists, meaning it simultaneously targets three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
Key Takeaways: Triple-Action Mechanism : Retatrutide uniquely activates GLP-1, GIP, and glucagon receptors, profoundly enhancing weight loss, glycemic control, and metabolic flexibility
doi: 10.1016/j.ejpb.2004.03.001 26 KocicIHomsekIDacevicMParojcicJMiljkovicB
Regarding safety, the overall incidence of AEs was similar between the dose and placebo groups
Although initially approved for adults with type 2 diabetes, Ozempic has demonstrated additional benefits in weight loss and reducing cardiovascular risks